ProCE Banner Activity

Managing Heavily Treatment–Experienced Patients With HIV: Questions and Answers

Clinical Thought
Heavily treatment–experienced patients with HIV are increasingly less common. However, by nature these patients are more complex and challenging. Here are expert answers to your outstanding questions on managing these patients.

Released: June 02, 2021

Expiration: June 01, 2022

Share

Faculty

Roger Bedimo

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Brian Wood

Brian Wood, MD

Assistant Professor of Medicine
Division of Allergy and Infectious Disease
University of Washington
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

ViiV Healthcare

Faculty Disclosure

Primary Author

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo MD, MS, FACP, has disclosed that he has received funds for research support from ViiV and consulting fees from Merck, Theratechnologies, and ViiV.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, and Pfizer.

Brian Wood, MD

Assistant Professor of Medicine
Division of Allergy and Infectious Disease
University of Washington
Seattle, Washington

Brian Wood, MD, has no relevant conflicts of interest to report.